Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Posted: December 7, 2024 at 2:50 am
FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings.
See original here:
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Posted in Global News Feed
Comments Off on Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in…
Posted: December 7, 2024 at 2:50 am
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Monday, December 9, 2024 at 4:30 pm EST to present data from COVALENT-103, the company’s Phase I trial of BMF-500, an investigational covalent FLT3 inhibitor developed using the proprietary FUSION™ System, in adult patients with relapsed or refractory acute leukemia.
Originally posted here:
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in...
Posted in Global News Feed
Comments Off on Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in…
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum…
Posted: December 7, 2024 at 2:50 am
WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced its development and commercialization partner, Torii Pharmaceutical Co. Ltd. (“Torii”), submitted a New Drug Application (“NDA”) of TO-208 (referred to as VP-102 and marketed as YCANTH® in the U.S.) for the treatment of Molluscum Contagiosum (“molluscum”) in Japan.
Posted in Global News Feed
Comments Off on Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum…
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Posted: December 7, 2024 at 2:50 am
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on December 3, 2024 to four new employees under Pacira’s Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors.
Go here to see the original:
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Posted in Global News Feed
Comments Off on Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
FluidForm Bio™ Announces Participation in the New England Venture Summit
Posted: December 7, 2024 at 2:50 am
WALTHAM, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that Mike Graffeo, CEO and co-founder, will delivery a company overview and conduct one-on-one meetings at the New England Venture Summit, which is being held December 10-11 in Boston, MA.
Read the original post:
FluidForm Bio™ Announces Participation in the New England Venture Summit
Posted in Global News Feed
Comments Off on FluidForm Bio™ Announces Participation in the New England Venture Summit
Virbac : Declaration of the number of shares and voting rights 11/2024
Posted: December 7, 2024 at 2:50 am
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS
Go here to read the rest:
Virbac : Declaration of the number of shares and voting rights 11/2024
Posted in Global News Feed
Comments Off on Virbac : Declaration of the number of shares and voting rights 11/2024
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
Posted: December 7, 2024 at 2:50 am
ISS Notes Need for Significant Board Change at AIM Due to Clinical Failure and Lack of Transparency
Original post:
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
Posted in Global News Feed
Comments Off on Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
Posted: December 7, 2024 at 2:50 am
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here
Read more from the original source:
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
Posted in Global News Feed
Comments Off on AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
Posted: December 7, 2024 at 2:50 am
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the "Debt Swap Agreements") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 337,750 Psyence Biomed common shares at a deemed price of US$3.88 per common share, in exchange for the discharging of the balance of Psyence Biomed's obligations due under the Debt Swap Agreements and a promissory note, dated January 25, 2024, issued by Psyence Biomed to the Company in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024.
Continue reading here:
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
Posted in Global News Feed
Comments Off on Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
GRI Bio to Participate in the Virtual Investor Closing Bell Series
Posted: December 7, 2024 at 2:50 am
Live webcast on Thursday, December 12th at 4:00 PM ET
Read the rest here:
GRI Bio to Participate in the Virtual Investor Closing Bell Series
Posted in Global News Feed
Comments Off on GRI Bio to Participate in the Virtual Investor Closing Bell Series
